Efikasi Valproat Sebagai Terapi Profilaksis Migraine

Oleh :

dr. Andriani Putri Bestari, Sp.S

Valproat diduga efektif sebagai terapi profilaksis pada migraine. Migraine merupakan penyakit kronik yang mengganggu kualitas hidup, dilaporkan mempengaruhi 36 juta warga Amerika dan merupakan salah satu penyakit yang paling prevalen di seluruh dunia.[1]

Tata laksana migraine meliputi terapi abortif dan profilaksis, di mana penderita dengan frekuensi serangan yang tinggi dan intensitas serangan yang berat memerlukan keduanya. Data dari American Migraine Prevalence and Prevention menunjukkan bahwa hanya 13% penderita migraine mendapatkan terapi profilaksis, dari setidaknya 38,8% penderita yang seharusnya dipertimbangkan untuk mendapatkan terapi profilaksis.[2]

Pilihan terapi profilaksis migraine meliputi banyak golongan obat, termasuk di dalamnya golongan beta bloker, antiepilepsi, antidepresan, dan antagonis kanal kalsium.[2]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache: The Journal of Head and Neck Pain. 2016;56(3):603-615.
2. Ambrosini A, Schoenen J. Preventive Episodic Migraine Treatment. Dalam: Pharmacological Management of Headaches. Springer, Cham. 2016. pp. 63-79.
3. Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurologic Clinics. 2019;37(4):753-770.
4. Parikh SK, Silberstein SD. Current Antiepileptic Drugs as Preventive Migraine Therapy. Current Treatment Options in Neurology. 2019;21(4):16.
5. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345.
6. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. European Journal of Neurology. 2009;16(9):968-981.
7. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews. 2013;6.
8. Mulleners WM, McCrory DC, Linde M. Antiepileptics in Migraine Prophylaxis: An Updated Cochrane Review. Cephalalgia. 2015;35(1):51-62.
9. Vecsei L, Majlath Z, Szok D, Csati A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opinion on Drug Safety. 2015;14(5):667-681.
10. Amanat M, Togha M, Agah E, Ramezani M, Tavasoli AR, Azizi Malamiri R, et al. Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia. 2019, 0333102419888485.
11. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience. 2012;122(2):60-68.
12. Dekhale GN, Sharma VS, Thakre MN, Kalikar M. Low-dose sodium valproate versus low-dose propranolol in prophylaxis of common migraine headache: A randomized, prospective, parallel, open-label study. Indian Journal of Pharmacology. 2019;51(4):255.
13. Vatsaki E, Straus S, Dogne JM, Burgos JG, Girard T, Martelletti P. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. The Journal of Headache and Pain. 2018;19(1):68.